RT Journal Article
SR Electronic
T1 Prediction of criticality in patients with severe Covid-19 infection using three clinical features: a machine learning-based prognostic model with clinical data in Wuhan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.27.20028027
DO 10.1101/2020.02.27.20028027
A1 Li Yan
A1 Hai-Tao Zhang
A1 Yang Xiao
A1 Maolin Wang
A1 Yuqi Guo
A1 Chuan Sun
A1 Xiuchuan Tang
A1 Liang Jing
A1 Shusheng Li
A1 Mingyang Zhang
A1 Ying Xiao
A1 Haosen Cao
A1 Yanyan Chen
A1 Tongxin Ren
A1 Junyang Jin
A1 Fang Wang
A1 Yanru Xiao
A1 Sufang Huang
A1 Xi Tan
A1 Niannian Huang
A1 Bo Jiao
A1 Yong Zhang
A1 Ailin Luo
A1 Zhiguo Cao
A1 Hui Xu
A1 Ye Yuan
YR 2020
UL http://medrxiv.org/content/early/2020/03/03/2020.02.27.20028027.abstract
AB Background COVID-19 appeared in Wuhan, China in December 2019, and since then it has immediately become a serious public health problem worldwide. No specific medicine against COVID-19 has been found until now. However, mortality risk in patients could potentially be predicted before they transmit to critically ill.Methods We screened the electronic records of 2,799 patients admitted in Tongji Hospital from January 10th to February 18th, 2020. There were 375 discharged patients including 201 survivors. We built a prognostic prediction model based on XGBoost machine learning algorithm and then tested 29 patients (included 3 patients from other hospital) who were cleared after February 19th.Results The mean age of the 375 patients was 58.83 years old with 58.7% of males. Fever was the most common initial symptom (49.9%), followed by cough (13.9%), fatigue (3.7%), and dyspnea (2.1%). Our model identified three key clinical features, i.e., lactic dehydrogenase (LDH), lymphocyte and High-sensitivity C-reactive protein (hs-CRP), from a pool of more than 300 features. The clinical route is simple to check and can precisely and quickly assess the risk of death. Therefore, it is of great clinical significance.Conclusion The three indices-based prognostic prediction model we built is able to predict the mortality risk, and present a clinical route to the recognition of critical cases from severe cases. It can help doctors with early identification and intervention, thus potentially reducing mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available once the paper gets accepted. The Python code is available upon request from YY.